Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04203498 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 139
- Enrollment target
NCT04203498 is a Phase 3 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 139 participants.
The verdict
NCT04203498, a Phase 3 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 139 participants
- Enrollment target
Study Summary
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
Interventions
- DRUG Placebo
- DRUG Nabiximols
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04203498
The ClinicalTrials.gov registry entry for NCT04203498 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04203498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04203498 about?
NCT04203498 is a clinical study titled "Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis". This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
What is the current status of trial NCT04203498?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2020-10-01. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04203498?
The interventions under investigation include: Placebo (DRUG), Nabiximols (DRUG).
Who is sponsoring clinical trial NCT04203498?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.